Pfizer nears $7.3B deal to acquire Metsera, targeting next-gen obesity treatments.
MET-097i shows 11.3% weight loss in trials and offers monthly dosing.
Acquisition positions Pfizer against Novo Nordisk and Eli Lilly in obesity market.
Pfizer is making a bold move in the pharmaceutical world by closing in on a $7.3 billion deal to acquire Metsera, a biotech firm focused on next-generation anti-obesity drugs, news platform Financial Times reported on Monday.
This acquisition underlines Pfizer’s fresh push into the booming weight-loss drug market, an area showing rapid growth as obesity rates climb worldwide.
After facing challenges with its own weight loss drug programs, Pfizer sees this as a strategic way to strengthen its portfolio and join the race against established leaders in obesity treatments.
Pfizer failed in its attempt to develop a weight loss drug, so they bought the competition.
Pfizer Inc (NYSE:PFE) is close to launching a $7.3 billion takeover offer for anti-obesity drug maker Metsera Inc (NASDAQ:MTSR), which could be the former’s biggest deal in two years while also giving it an edge in the weight loss drug market, the Financial Times reported on Monday.
Pfizer’s pursuit of Metsera appears to stem from the company’s attempts to break into the lucrative weight loss drug industry, after its own experimental drug danuglipron flopped in clinical trials earlier this year.